oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 605 )

2018 ( 845 )

2017 ( 787 )

2016 ( 1145 )

Custom range...

Search Results: 1 - 10 of 466827 matches for " Sumati A. Rao "
All listed articles are free for downloading (OA Articles)
Page 1 /466827
Display every page Item
A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting  [PDF]
Debra A. Patt, Debra Rembert, Menaka Bhor, Debajyoti Bhowmik, Sumati A. Rao
Journal of Cancer Therapy (JCT) , 2014, DOI: 10.4236/jct.2014.512110
Abstract: Background: Following approval of ipilimumab, this observational cohort study (CA184-332) was initiated to describe patient and disease characteristics, patterns of care, survival, and adverse events (AEs) in advanced melanoma (AM) patients treated with first-line ipilimumab in realworld US community practice. Methods: Adult patients with treatment-naive AM who received ≥1 dose of ipilimumab 3 mg/kg between April 2011 and September 2012 were retrospectively identified at US Oncology sites. Clinical data were abstracted from patient medical records. Results: Median age of the 157 patient cohorts was 66 years (range 21 - 91). 68.2% were male, and 90.5% had a cutaneous primary site. At ipilimumab initiation, 80.9% of patients had an ECOG performance status of 0 or 1; 54.1% were stage M1c; 34.4% had brain metastases; 24.8% had elevated lactate dehydrogenase, and 13.4% were positive for BRAF mutation. All 4 cycles of ipilimumab were completed by 55.8% of patients. At a median follow-up of 8.5 months (range 2.9 - 15.0), median overall survival was 11.5 months (95% CI: 8.9 - 16.6) and 1-year survival was 46.7% (95% CI: 38.1 - 54.9). During ipilimumab treatment, AEs were experienced by 63.7% of patients. The most frequent AEs were gastrointestinal (41.4%; diarrhea in 19.1%) and skin-related (28.0%; rash in 17.8%); 17.8% of patients had an AE that led to ipilimumab discontinuation. Conclusions: These real-world results are consistent with those from clinical trials and provide evidence supporting the effectiveness and safety of first-line ipilimumab 3 mg/kg monotherapy in patients with AM treated in a community practice setting.
Bacterial vaginosis with special reference to anaerobes
Sumati A,Saritha N
Indian Journal of Pathology and Microbiology , 2009,
Abstract: Aims: This study was undertaken to assess the prevalence of bacterial vaginosis (BV) and to estimate the prevalence of anaerobic organisms in vaginal discharge of women suffering from bacterial vaginosis. Settings and Design: Patients attending the Obstetrics and Gynecology Department of a Medical College Hospital. A one year cross-sectional study. Methods and Materials: High vaginal swabs taken from 174 female patients complaining of abnormal vaginal discharge. BV was diagnosed by clinical composite criteria and by gram stain. Anaerobes were isolated and identified from the discharge. Statistical Analysis Used: Chi square test, with level of significance set at a value of P< 0.05. Results: BV was diagnosed in 68.39% of the cases by using clinical composite criteria and in 58.4% of the cases by gram stain. Anaerobic culture isolation of vaginal swabs revealed that out of 174 cases 143 (82.65%) were culture positive for anaerobes. Bacteroides were significantly raised in BV as compared with non bacterial vaginosis (NBV; < 0.05%). Conclusions: Anaerobic bacteria are important pathogens in the causation of bacterial vaginosis along with other aerobic organisms. Bacteroides and peptostreptococci are significantly raised in BV.
Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab  [PDF]
Ahmad Tarhini, Shelby L. Corman, Sumati Rao, Kim Margolin, Xiang Ji, Sonam Mehta, Marc F. Botteman
Journal of Cancer Therapy (JCT) , 2015, DOI: 10.4236/jct.2015.610091
Abstract: Background: To describe healthcare costs, excluding ipilimumab drug costs, in patients with advanced melanoma receiving ipilimumab in the US community practice setting. Methods: This was a retrospective chart review of unresectable stage III/IV melanoma patients who received first-line ipilimumab monotherapy between 04/2011 and 09/2012. Healthcare resource utilization included inpatient, emergency, specialist and hospice visits, laboratory tests, radiation, surgeries, and nursing home stays. Publicly available US unit costs were applied to each resource type to estimate costs, which were analyzed by time periods: during ipilimumab treatment, post-ipilimumab treatment (post-regimen), and within 90 days prior to death (pre-death). Generalized linear mixed models were used to explore cost predictors during the treatment period, on a per-dose-interval basis, defined as the time between ipilimumab doses. Results: Data were abstracted from 273 patient charts at 34 sites. Excluding ipilimumab drug costs, total monthly costs during the treatment regimen, post-regimen, and pre-death periods were $690, $2151, and $5123, respectively. Total healthcare costs were 27 times higher during dose intervals with a grade 3/4 adverse event compared with intervals without a grade 3/4 adverse event. Eastern Cooperative Oncology Group performance status ≥ 2 (vs 0) was also associated with significantly higher cost per dose interval. Conclusions: In this population, monthly costs exclusive of drug were significantly lower during the treatment period than in subsequent periods. Unfavorable ECOG PS was associated with significant increases in cost per dose interval. Grade 3/4 adverse events were associated with a marked increase in healthcare costs, but occurred in a small proportion of dose intervals.
Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment  [PDF]
Kathleen Beusterien, Mark R. Middleton, Peter Feng Wang, Sumati Rao, Srividya Kotapati, Javier Sabater, Baiju Aurora, John F. P. Bridges
Journal of Cancer Therapy (JCT) , 2017, DOI: 10.4236/jct.2017.81004
Abstract: Objective: To evaluate and compare patient and physician preferences for the benefits and risks of currently available adjuvant melanoma treatments. Methods: Patients with stage II/III melanoma and oncologists in the USA were recruited from 6 clinical sites and an online panel to complete a survey. Preferences were assessed using a paired comparison discrete choice experiment that allowed for opt-out (i.e. no treatment). The treatments comprised 7 attributes, each with 3 levels associated with pegylated interferon, high-dose interferon, and ipilimumab. Attributes included efficacy outcomes, dosing regimen, and risks of moderate to severe toxicities. In addition, open-ended maximum acceptable risk (MAR) questions assessed tradeoffs between toxicity risk and efficacy. Results: 142 patients (45 stage II; 97 stage III) chose a treatment in 78% of the choice tasks, while physicians (N = 127) chose treatment 79% of the time. The rankings of relative attribute importance were concordant between the patients and physicians for the top 4: 10-year survival in metastatic melanoma, fatigue risk, 3-year recurrence-free survival (RFS), and depression risk. Patients and physicians valued the difference in 21% survival versus no survival benefit about 3 and 4 times as much, respectively, as reducing diarrhea risk from 41% to 1% or reducing depression risk from 40% to 1%. The MAR of severe diarrhea and of a life-threatening event increased as the chance of 3-year RFS increased, with patients reporting higher risks than physicians. Conclusion: Patients and physicians were concordant in their preferences in adjuvant melanoma, preferring treatment versus none and judging potential efficacy to outweigh risks of toxicities.
Some Integral Type Fixed Point Theorems in Dislocated Metric Space  [PDF]
Dinesh Panthi, Panda Sumati Kumari
American Journal of Computational Mathematics (AJCM) , 2016, DOI: 10.4236/ajcm.2016.62010
Abstract: In this article, we establish a common fixed point theorem satisfying integral type contractive condition for two pairs of weakly compatible mappings with E. A. property and also generalize Theorem (2) of B.E. Rhoades [1] in dislocated metric space.
Causal Set Topology
Sumati Surya
Physics , 2007,
Abstract: The Causal Set Theory (CST) approach to quantum gravity is motivated by the observation that, associated with any causal spacetime (M,g) is a poset (M,<), with the order relation < corresponding to the spacetime causal relation. Spacetime in CST is assumed to have a fundamental atomicity or discreteness, and is replaced by a locally finite poset, the causal set. In order to obtain a well defined continuum approximation, the causal set must possess the requisite intrinsic topological and geometric properties that characterise a continuum spacetime in the large. The continuum approximation thus sets the stage for the study of topology in CST. We review the status of causal set topology and present some new results relating poset and spacetime topologies. The hope is that in the process, some of the ideas and questions arising from CST will be made accessible to the larger community of computer scientists and mathematicians working on posets.
Directions in Causal Set Quantum Gravity
Sumati Surya
Physics , 2011,
Abstract: In the causal set approach to quantum gravity the spacetime continuum arises as an approximation to a fundamentally discrete substructure, the causal set, which is a locally finite partially ordered set. The causal set paradigm was elucidated in a classic paper by Bombelli, Lee, Meyer and Sorkin in 1987. While early kinematical results already showed promise, the program received a substantial impetus about a decade ago with the work of Rideout and Sorkin on a classical stochastic growth dynamics for causal sets. Considerable progress has been made ever since in our understanding of causal set theory while leaving undisturbed the basic paradigm. Recent highlights include a causal set expression for the Einstein-Hilbert action and the construction of a scalar field Feynman propagator on a fixed causal set. The aim of the present article is to give a broad overview of the results in causal set theory while pointing out directions for future investigations.
Evidence for a Phase Transition in 2D Causal Set Quantum Gravity
Sumati Surya
Physics , 2011, DOI: 10.1088/0264-9381/29/13/132001
Abstract: We present evidence for a phase transition in a theory of 2D causal set quantum gravity which contains a dimensionless non-locality parameter $\epsilon \in (0,1]$. The transition is between a continuum phase and a crystalline phase, characterised by a set of covariant observables. For a fixed size of the causal set the transition temperature $\beta_c^{-1}$ decreases monotonotically with $\epsilon$. The line of phase transitions in the $\beta_c^2$ v/s $\epsilon$ plane asymptotes to the infinite temperature axis, suggesting that the continuum phase survives the analytic continuation.
Cyclic Statistics In Three Dimensions
Sumati Surya
Mathematics , 2003, DOI: 10.1063/1.1738189
Abstract: While 2-dimensional quantum systems are known to exhibit non-permutation, braid group statistics, it is widely expected that quantum statistics in 3-dimensions is solely determined by representations of the permutation group. This expectation is false for certain 3-dimensional systems, as was shown by the authors of ref. [1,2,3]. In this work we demonstrate the existence of ``cyclic'', or $Z_n$, {\it non-permutation group} statistics for a system of n > 2 identical, unknotted rings embedded in $R^3$. We make crucial use of a theorem due to Goldsmith in conjunction with the so called Fuchs-Rabinovitch relations for the automorphisms of the free product group on n elements.
Ehlers-Danlos syndrome with monostotic fibrous dysplasia
Rao A
Journal of Postgraduate Medicine , 1979,
Abstract: An unusual case of Ehlers-Danlos syndrome with monostotic fibrous dysplasia of the humorus is presented. The other orthopae-dic manifestations, its complications and associated features are re-viewed and summarised.
Page 1 /466827
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.